drugset / Trial / NCT06181019

Acupuncture Combined With Mirabegron in the Treatment of OAB

NCT06181019

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Introduction: As conventional treatments for overactive bladder (OAB) have not yet shown satisfactory results, new approaches are needed. Therefore, this study aimed to investigate the efficacy and safety of acupuncture combined with mirabegron for the treatment of OAB. Methods: This prospective cohort study enrolled 80 OAB patients who were then divided into control and treatment groups using a randomized number-table method. The control group was administered mirabegron alone (50 mg/day), while the treatment group was administered mirabegron orally along with acupuncture at the following points: guanyuan (CV4), zhongji (CV3), and sanyinjiao (SP6). The OAB symptom score (overactive bladder syndrome score \[OABSS\]), voiding, urgency, nocturia, incontinence, and incidence of related adverse events were compared between the two groups at baseline and after 4, 8, and 12 weeks of treatment.

Timeline

Start
2021-12-01
Primary completion
2023-03-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirabegron Other / unclassified 50 mg Oral

Indications